spacer
home > ict > autumn 2017 > helping hands
PUBLICATIONS
International Clinical Trials

Helping Hands

To be able to discuss how site nursing support benefits
the clinical trial industry and home care in particular, the
ongoing obstacles need to be understood. Clinical trial sites
face many challenges, such as engaging minority groups
efficiently and quickly identifying patients, while coping
with increased work load due to the small pool of available
research locations.

Equal Representation

One barrier that continues to impact clinical trials is the
enrolment of ethnic minority groups. These classes remain
underrepresented in treatment experiments that could
save their lives. However, some diseases are more prevalent
in different racial and ethnic groups – African Americans
are approximately 70% more likely to be diagnosed with
diabetes, for example (1). Therefore, to produce a drug
that will best treat these patients they must be included
in clinical trials.

This remains an obstacle for several reasons: a lack of
minority principal investigators (PI), a lack of awareness
of clinical trials among these groups or patients living too
far from an enrolling location.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Helena Baker is Vice President of Nursing at Medical Research Network and has over 32 years’ experience in nursing and healthcare. She previously worked at the Royal London Hospital in Whitechapel, Ferring Pharmaceuticals Ltd and St Bartholomew’s Hospital in the UK, as well as acting as a healthcare analyst to the pharmaceutical industry.
spacer
Helena Baker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement